Maartina J. P. Oosterom-Eijmael

Maartina J. P. Oosterom-Eijmael

Auto-generated profile, based on publicly available information

Maartina J. P. Oosterom-Eijmael

Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SESarah A. van Eeghen
Sarah A. van Eeghen
NNNatalie J. Nokoff
Natalie J. Nokoff
TVTaryn G. Vosters
Taryn G. Vosters
MOMaartina J.P. Oosterom-Eijmael
Maartina J.P. Oosterom-Eijmael
DCDavid Z.I. Cherney
David Z.I. Cherney
DRDaniël H. van Raalte
Daniël H. van Raalte
Sexual dimorphism plays an important role in the pathogenesis and progression of CKD. Men with CKD often exhibit faster kidney function decline, leading to higher rates of kidney failure and mortality compared with women. Studies suggest that sex hormones may influence this apparent dimorphism, although the mechanisms underlying these influences remain poorly understood. In this review, we first summarize recent findings on sex differences in the prevalence and progression of CKD. Subsequently, we will focus on ( 1 ) the role of sex hormones in these sex differences, ( 2 ) kidney structural and hemodynamic differences between men and women, ( 3 ) the influence of sex hormones on pathophysiological processes leading to kidney disease, including glomerular hyperfiltration and key pathways involved in kidney inflammation and fibrosis, and finally, focus on the consequences of the underrepresentation of women in clinical trials. Understanding these sex differences is critical for advancing precision medicine and improving outcomes for both men and women with CKD.

29 March 2025 in Journal of Clinical Anesthesia
Verified
Journal Article
Open access
LSLars I.P. Snel
Lars I.P. Snel
MOMaartina J.P. Oosterom-Eijmael
Maartina J.P. Oosterom-Eijmael
Elena RampanelliElena Rampanelli
Elena Rampanelli
YLYugeesh R Lankadeva
Yugeesh R Lankadeva
MPMark Plummer
Mark Plummer
AHAbraham Hulst
Abraham Hulst
Sodium-glucose transporter-2 (SGLT2) inhibitors reduced the incidence of acute kidney injury in large cardiovascular outcome trials in patients with chronic heart and kidney failure. Acute kidney injury is a common complication following cardiac surgery. We hypothesized that perioperative SGLT2 inhibition could reduce kidney injury after cardiac surgery, measured with the biomarker neutrophil gelatinase-associated (NGAL). In this open-label phase IV, randomized, parallel-group, pilot study, adult patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomized to receive either an SGLT2 inhibitor, empagliflozin (10 mg; oral) once daily, from three days before surgery until postoperative day two, or standard-of-care. The primary outcome was the between-group difference of serum NGAL on the second postoperative day. Moreover, other biomarkers for acute kidney injury were measured, including serum kidney injury molecule-1 (KIM-1), hypoxia-inducible factor-1 alpha (HIF-1α), and urine NGAL/Creatinine and KIM-1/Creatinine ratios. Additional outcomes included acute kidney injury incidence within the first seven days following cardiac surgery according to Kidney Disease: Improving Global Outcomes criteria and metabolic parameters, including ketone body concentrations and glycemic control. Between March 2022 and April 2023, 55 patients were included (sex: 73 % male, age: 66 ± 10 years, BMI: 28 ± 4 kg/m2, empagliflozin n = 25, control n = 30) in the intention-to-treat analysis. There were no significant between-group differences in serum and urine NGAL or KIM-1. However, empagliflozin significantly reduced the incidence of acute kidney injury (20 % vs 66.7 %; absolute difference 46.7 %, 95 % CI, -69.7 - -23.6; P < .001). A significant increase in serum HIF-1α after surgery was solely observed in the control group. We observed no between-group differences in the incidence of (euglycemic) ketoacidosis or hypoglycemic events. In this pilot study, perioperative SGLT2 inhibition was not associated with lower NGAL levels. We observed that SGLT2 inhibition reduced the incidence of acute kidney injury in this small study population. As the results of this pilot study are hypotheses-generating, further validation is needed in a large-scale, double-blind, placebo-controlled, randomized trial, which is currently ongoing.

4 June 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
MOMaartina J.P. Oosterom-Eijmael
Maartina J.P. Oosterom-Eijmael
JHJeroen Hermanides
Jeroen Hermanides
DRDaniel H. van Raalte
Daniel H. van Raalte
AHAbraham H. Hulst
Abraham H. Hulst

18 June 2024 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Open access
MOMaartina J.P. Oosterom-Eijmael
Maartina J.P. Oosterom-Eijmael
JHJeroen Hermanides
Jeroen Hermanides
DRDaniël H. van Raalte
Daniël H. van Raalte
IKImre W.K. Kouw
Imre W.K. Kouw
JDJ. Hans DeVries
J. Hans DeVries
AHAbraham Hulst
Abraham Hulst
The objectives of the current research were to evaluate the accuracy and reliability of continuous glucose monitoring (CGM) in patients undergoing cardiac surgery and assess the impact of preoperative liraglutide administration on perioperative glucose control as captured by CGM. This was a prospective, single-center, prespecified analysis of the GLOBE trial, a randomized controlled trial comparing preoperative liraglutide treatment to placebo in patients undergoing cardiac surgery. The work took place at a single-center academic hospital in the Netherlands. Twenty-five patients undergoing cardiac surgery were recruited from the hospital's cardiac surgery department. Participants received the Dexcom G5 CGM system from the day before surgery until discharge from the intensive care unit after surgery. Additionally, participants were randomized to receive either preoperative liraglutide or placebo. Arterial blood gas (ABG) glucose measurements were collected as a reference and matched to CGM readings to assess accuracy and reliability. In 240 paired CGM-ABG glucose measurements, the mean absolute relative difference was 14.4 ± 12.5%. Temporary sensor interruption occurred mainly intraoperatively (92% of patients). The median duration of intraoperative sensor interruption was 65 (48-95) minutes. Liraglutide increased glycemic time in range 72% versus 47% in the control group (absolute difference 25%, 95% confidence interval -41.4 to -8.9, p = .004). Despite intraoperative sensor interruption, CGM seems an accurate method for semi-invasive, real-time assessment of blood glucose levels. CGM can provide a detailed observation of the pre- and postoperative glycemic trajectory, demonstrating increased time in range following perioperative liraglutide treatment compared with placebo.

16 May 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
MOMaartina Oosterom-Eijmael
Maartina Oosterom-Eijmael
NONelson P Monteiro de Oliveira
Nelson P Monteiro de Oliveira
ENEd D Niesten
Ed D Niesten
MTMartijn Tolsma
Martijn Tolsma
FSFerdinand Tf Snellen
Ferdinand Tf Snellen
AHAbraham H Hulst
Abraham H Hulst
Introduction Acute kidney injury (AKI) is a major complication after cardiac surgery and is associated with postoperative morbidity and mortality. Currently, no effective therapy exists to reduce the incidence of postoperative AKI. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective in reducing AKI in outpatient settings for patients with chronic kidney disease. We hypothesised that perioperative SGLT2 inhibition will also reduce AKI incidence after cardiac surgery according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Methods and analysis We designed a multicentre, randomised, placebo-controlled, triple-blinded, superiority trial. A total of 784 patients, aged above 18 years, undergoing cardiac surgery will be included with stratification for sex and type 2 diabetes in a 1:1 ratio. Patients will receive either dapagliflozin 10 mg or placebo from the day before until 2 days after surgery. Serum creatinine will be measured preoperatively and daily for the first 7 days after the operation, and urine output will be measured until the urinary catheter is removed. The primary outcome is the incidence of postoperative AKI according to the KDIGO criteria. Ethics and dissemination The medical ethics committee of the Amsterdam University Medical Centre (UMC) and the Dutch competent authority approved the study protocol (currently, version 9, 19 January 2024). This is an investigator-initiated study. The Amsterdam UMC, as sponsor, retains ownership of all data and publication rights. After completion of the trial, results will be disseminated to participants, patient societies and physicians via a network meeting and digital newsletter. Results will be submitted for publication in a peer-reviewed international medical journal and presented on (inter)national congresses. Trial registration number Clinicaltrials.gov identifier: NCT05590143.

8 December 2025 in BJA Education
Verified
Journal Article
Open access
MOM.J.P. Oosterom-Eijmael
M.J.P. Oosterom-Eijmael
HHH. Hermanns
H. Hermanns
YLY.R. Lankadeva
Y.R. Lankadeva
AHA.H. Hulst
A.H. Hulst